MedTrace Logo

Use of Warfarin After the First Trimester in Pregnant Women With APS

NCT02303171 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-10-31

No results posted yet for this study

Summary

Evaluation of shifting to oral vitamin K antagonist after the first trimester instead of using low molecular weight heparin (LMWH) throughout pregnancy in pregnant women with antiphospholipid syndrome (APS)

Conditions

  • Recurrent Miscarriage
  • Antiphospholipid Syndrome

Interventions

DRUG

Enoxaparin

Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)

DRUG

Warfarin

Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy

Sponsors & Collaborators

  • Mohamed Sayed Abdelhafez

    lead OTHER

Principal Investigators

  • Mohamed I Eid, Dr · Mansoura University

  • Mohamed S Abdelhafez, Dr · Mansoura University

  • Abdelmageed F Mashaly, Prof · Mansoura University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2024-12-31
Completion
2025-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02303171 on ClinicalTrials.gov